Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab-Reference-Cited by-同舟云学术

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Published:2024-01-27 Issue:1 Volume:12 Page:175-182
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Bernabé Reyes^ORCID,Liu Stephen V.,Sánchez-Gastaldo Amparo,Alonso García Miriam

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40487-023-00257-0.pdf

Reference31 articles.

1. Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res. 2016;170:301–22.

2. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018;7:69–79.

3. Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.

4. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39.

5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology: small cell lung cancer. Version 2.2022. 2021. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 10 Feb 2022.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report;Current Oncology;2024-06-27